Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTLBiotechnology
+$0.03 today
- Market cap
- $133.64M
- Beta
- 1.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.77
Volume 1.21M
Average 2.00M
ZNTL Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns positive
Q1 FY2026 other income / expenses was $2.62M, compared with -$2.66M a year earlier. Trailing-twelve-month other income / expenses was $21.47M.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other income / expenses holds near $2.62M or moves back toward the trailing-twelve-month quarterly average of $5.37M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 16.19M USD
- Year-over-year change
- -36.5%
- 4-year CAGR
- -24.6%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.19M | -36.5% |
| FY2024 | 2024-12-31 | 25.5M | +286.2% |
| FY2023 | 2023-12-31 | 6.6M | +164.1% |
| FY2022 | 2022-12-31 | (10.3M) | -120.5% |
| FY2021 | 2021-12-31 | 50.15M | — |
Other Income / Expenses vs competitors
How ZNTL compares with its peers on the latest reported figures
- ZNTL's LTM Mar 2026 other income / expenses of $21.47M is the highest of the 11 companies compared; the peer median is $2.54M.
- Its year-over-year change of +277.4% is the highest of 11, against a peer median of -62.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.47M | +277.4% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $6.9M | -92.4% | +251.1% | — |
| LTM Mar 2026 | $6.66M | +277.0% | — | — | |
| LTM Mar 2026 | $5.99M | -61.1% | -42.7% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $5M | -50.6% | +65.3% | — |
| LTM Mar 2026 | $2.79M | -35.2% | +24.9% | 279.0% | |
| LTM Mar 2026 | $2.3M | -64.6% | -16.7% | — | |
| LTM Mar 2026 | $1.13M | +25.3% | — | — | |
| LTM Mar 2026 | -$5.37M | -124.3% | — | 11.9% | |
| LTM Mar 2026 | -$7.37M | -116.5% | — | 4.7% | |
| LTM Mar 2026 | -$38.64M | -613.7% | — | 38.8% | |
| Peer median (excluding ZNTL) | $2.54M | -62.9% | +24.9% | 25.4% | |
Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 67.43M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 67.43M | 0 |
| Gross Margin | — | — | — | 100.0% | — |
| Research & Development | 175.6M | 172.73M | 235.16M | 167.77M | 107.3M |
| Selling, General & Admin | 40.94M | 54.55M | 59.4M | 87.12M | 37.72M |
| Operating Expenses | 216.54M | 227.29M | 299.51M | 258.62M | 152.81M |
| Depreciation & Amortization | 544K | 1.43M | 1.39M | 1.29M | 739K |
| EBITDA | (207.2M) | (233.58M) | (247.6M) | (186.17M) | (144.27M) |
| EBITDA Margin | — | — | — | -276.1% | — |
| Operating Income | (216.54M) | (227.29M) | (299.51M) | (191.19M) | (152.81M) |
| Operating Margin | — | — | — | -283.6% | — |
| Interest Income | 0 | 2.26K | 0 | 0 | 0 |
| Interest Expense | 0 | 2.58M | 0 | 0 | 0 |
| Other Income / Expenses | 50.15M | (10.3M) | 6.6M | 25.5M | 16.19M |
| Income Before Tax | (166.39M) | (237.58M) | (292.91M) | (165.69M) | (136.62M) |
| Pre-Tax Margin | — | — | — | -245.7% | — |
| Income Tax Expense | (297K) | (469K) | (601K) | 177K | 442K |
| Net Income | (158.73M) | (236.81M) | (292.19M) | (165.84M) | (137.06M) |
| Net Margin | — | — | — | -246.0% | — |
| EPS (Basic) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) |
| EPS (Diluted) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) |
| Weighted Avg Shares | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M |
| Weighted Avg Shares (Diluted) | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M |
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.